. All compounds tested against HT2RA/DRD2/HRH1 with their respective ranks and binding constants Table S2 . All compounds tested against KOR/MOR with their respective ranks and binding constants Figure S1 . Retrospective enrichment plots for the on-targets DRD2 and 5HT2RA
(Left) Enrichment of own HT2RA and DRD2 ChEMBL annotated ligands for the on-target HT2RA and DRD2 homology models against a background of property-matched decoys is high. (Right) There is no enrichment of HT2RA and DRD2 ChEMBL annotated ligands by the antitarget HRH1 crystal structure.
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Figure S2. Retrospective enrichment plots for the off-target HRH1
High enrichment of own HRH1 ChEMBL annotated ligands against the antitarget HRH1 crystal structure.
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Figure S3. Effect of fingerprint choice for discriminating HRH1 binding
Distribution of T c measured between all compounds tested and the annotated HRH1 ChEMBL binders, using MACCS structural keys, a linear fingerprint, and a dendritic fingerprint. Distribution shown for the HRH1 docking false negatives and true negatives. Figure S4 . Glide docking and MM/GBSA rescoring of compounds tested against DRD2/5HT2RA/HRH1
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The MM/GBSA score is compared to the experimental affinity for each receptor, respectively, and the circles are sized by the HRH1 MM/GBSA score (larger size corresponds to a less negative score, i.e. predicted to bind with lower affinity) S9 Figure S5 . Comparison of the HRH1 binding site crystal structure to the ENM model HRH1 binding site crystal structure (left, cyan) and the larger binding site of the ENM model (right, magenta) used for additional screening. While the position of the key aminergic aspartate D 3.32 is relatively unchanged, movement of three key hydrophobic residues (W 4.57 , F 6.52 , and W 6.48 ) makes for a much larger binding site.
